Ascendiant Capital Markets Comments on PSTV Q1 Earnings

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Equities researchers at Ascendiant Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for shares of Plus Therapeutics in a research report issued to clients and investors on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo forecasts that the company will post earnings of ($0.74) per share for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share. Ascendiant Capital Markets also issued estimates for Plus Therapeutics’ Q2 2027 earnings at ($0.74) EPS, Q3 2027 earnings at ($0.60) EPS and Q4 2027 earnings at ($0.60) EPS.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings data on Thursday, March 12th. The company reported $6.25 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $6.28. The company had revenue of $1.37 million during the quarter, compared to analyst estimates of $1.23 million.

Several other equities analysts have also recently weighed in on PSTV. Wall Street Zen raised Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $25.00 price target (down from $50.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Finally, Lake Street Capital assumed coverage on Plus Therapeutics in a report on Tuesday, February 3rd. They set a “buy” rating and a $50.00 price target for the company. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $58.00.

Plus Therapeutics Price Performance

Shares of NASDAQ PSTV opened at $5.41 on Tuesday. The stock has a market capitalization of $37.12 million, a PE ratio of -0.17 and a beta of 1.03. The business has a fifty day moving average price of $6.16 and a two-hundred day moving average price of $11.07. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $30.50.

Hedge Funds Weigh In On Plus Therapeutics

A number of institutional investors have recently modified their holdings of PSTV. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the 2nd quarter worth $41,000. Altium Capital Management LLC acquired a new position in shares of Plus Therapeutics during the 3rd quarter worth $628,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics during the 3rd quarter worth $100,000. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics during the 3rd quarter worth $46,000. Finally, Geode Capital Management LLC raised its holdings in shares of Plus Therapeutics by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after buying an additional 589,544 shares in the last quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.